The ALDH2 enzyme, traditionally understood as a key player in clearing toxic aldehydes, now emerges as a pivotal regulator of cellular protein synthesis. Under normal physiological conditions, ALDH2 interacts directly with the eIF3E subunit, a crucial component of the translational initiation factor complex. This interaction acts as a molecular safeguard, maintaining homeostasis by restricting the production of deleterious proteins within cardiomyocytes. In individuals harboring the ALDH2 mutation, structural alterations in the enzyme disrupt this vital interaction, unleashing unrestrained protein synthesis that precipitates ferroptosis—a unique and iron-dependent mode of regulated cell death characterized by overwhelming lipid peroxidation.

Ferroptosis, distinct from apoptosis and necrosis, has recently garnered increasing attention in pathophysiological contexts, especially in ischemic heart diseases. The study meticulously correlates the surge of ferroptotic markers—such as severe depletion of the antioxidant coenzyme Q10 and accumulation of bioactive lipid peroxides—with the exacerbated myocardial damage observed in mutation carriers. These molecular events synergize to inflict irreversible injury to cardiomyocytes during acute myocardial ischemia, culminating in impaired cardiac function and heart failure.

This research involved an extensive clinical component, comprising 177 Chinese patients presenting with acute heart failure post-myocardial infarction. Genotypic analyses stratified patients according to the presence or absence of the ALDH2 mutation. Strikingly, those with the mutation exhibited noticeably aggravated cardiac dysfunction, validating the mutation’s deleterious role in clinical outcomes. These human data were further substantiated through animal models genetically engineered to express mutant ALDH2, wherein therapeutic interventions targeting ferroptosis yielded significant cardioprotective effects.

The mechanistic insights rooted in molecular biology detail how the loss of ALDH2-eIF3E binding converts the translational machinery into a “selective mode.” In this aberrant state, ribosomes preferentially synthesize proteins that foster lipid peroxidation and ferroptosis, forming a vicious cycle that accelerates cardiac tissue destruction. This paradigm shift redefines ALDH2’s function from a metabolic enzyme to a critical translational regulator, providing an explanatory framework for the heightened vulnerability of mutation carriers subjected to ischemic insults.

Therapeutically, the study positions ferroptosis inhibition as a promising strategy. Utilizing pharmacological agents known as ferroptosis inhibitors and iron chelators, alongside genetic modulation of protein translation pathways, researchers demonstrated marked improvement in post-infarction cardiac parameters in murine models. These findings portend the potential for personalized medicine approaches, particularly for East Asian populations disproportionately affected by this mutation, employing targeted treatments that prevent ferroptotic cardiomyocyte death and attenuate heart failure risk.

Beyond its direct clinical ramifications, the study advances the broader scientific understanding of how genetic variants co-opt intricate cellular processes to drive disease pathogenesis. The demonstration that a mutation originally notorious for its metabolic disturbance also commandeers the translational apparatus underscores the complexity of genotype-phenotype correlations in cardiovascular diseases. Moreover, it emphasizes the need for refined diagnostic tools incorporating genomics and proteomics to facilitate early risk stratification and intervention.

This pioneering work is a product of a robust collaboration involving leading institutions such as the Shanghai Institute of Nutrition and Health of the Chinese Academy of Sciences, the Naval Medical University, Sun Yat-sen University, Fudan University, and Harbin Medical University. Financial support was provided by eminent funding bodies including the National Natural Science Foundation of China, Shenzhen Medical Research Fund, Research Grants Council of Hong Kong, and CityUHK.

The study’s arrival sparked significant interest within the scientific community, inspiring a dedicated editorial in Circulation authored by Professor Zhu Yi, a foremost cardiovascular expert from Tianjin Medical University. This commentary lauds the innovative discovery of selective mRNA translation’s role in ferroptosis post-myocardial infarction, thereby cementing the study’s status as a transformative milestone in cardiovascular medicine.

Looking ahead, the implications of this study are manifold. It paves the way for diagnostic genotyping to identify high-risk ALDH2 mutation carriers, allowing tailored “anti-ferroptosis” therapeutic regimens to mitigate extensive myocardial damage. Such precision medicine strategies hold promise not only in improving individual outcomes but also in alleviating the substantial healthcare burden imposed by ischemic heart disease across East Asia and potentially other affected populations worldwide.

In summary, the discovery that the ALDH2 mutation precipitates ferroptosis through dysregulated protein translation offers compelling evidence of the genetic underpinnings governing myocardial injury severity. By elucidating these cellular and molecular pathways, Professor Yin Huiyong and his team have opened new frontiers in understanding and combating cardiovascular diseases, emphasizing the critical role of targeted interventions tailored to genetic risk profiles.

Subject of Research: People

Article Title: ALDH2/eIF3E Interaction Modulates Protein Translation Critical for Cardiomyocyte Ferroptosis in Acute Myocardial Ischemia Injury

News Publication Date: 20-Oct-2025

Web References:

• DOI link to research article
• Editorial commentary

References: Study published in Circulation, October 2025

Image Credits: City University of Hong Kong

Keywords: ALDH2 mutation, Asian Flush Syndrome, ferroptosis, myocardial infarction, cardiac dysfunction, protein translation, eIF3E, lipid peroxidation, coenzyme Q10, cardiovascular genetics, ischemic heart disease, targeted therapy

Myocardial ischemia-reperfusion injury (IRI) remains a major clinical challenge, with variations in tissue damage observed depending on the time of day when the injury occurs. The mystery behind this temporal variability has persisted despite advances in cardiovascular research. Here, the authors present compelling evidence implicating the BMAL1–HIF2A complex as a pivotal driver of diurnal changes in myocardial injury, providing a molecular explanation for these daily fluctuations.

Central to their discoveries is the gene Areg, which encodes Amphiregulin (AREG), a member of the epidermal growth factor family. The study reveals that among several potential HIF2A target genes upregulated during myocardial IRI, Areg displays the most pronounced diurnal fold change. Specifically, AREG levels peak in the affected heart tissue at Zeitgeber Time 8 (ZT8), resembling mid-light phase, whereas levels decline by ZT20, corresponding to the early dark phase. This rhythmic expression pattern of Areg mirrors the presence and activity of the BMAL1–HIF2A heterodimer within the cardiomyocytes of the ischemic border zone.

Detailed immunofluorescence analysis corroborated these findings, localizing elevated AREG expression precisely to cardiomyocytes adjacent to the infarcted region at ZT8. Remarkably, other cardiac cell types such as fibroblasts and smooth muscle cells exhibited negligible AREG induction, underscoring a cell-type-specific regulatory mechanism. This spatial restriction coincides with nuclear co-localization of BMAL1 and HIF2A in the same region and circadian time frame, supporting the hypothesis that the heterodimer directly regulates Areg transcription in response to ischemic stress.

Moving beyond in vivo studies, the team employed synchronized human cardiomyocytes (HCMs) cultivated in vitro under controlled circadian conditions. Upon exposure to hypoxia (1% oxygen for 4 hours), these cells exhibited a starkly time-dependent induction of AREG mRNA. Intriguingly, robust transcript induction occurred at circadian time 32 (CT32), equivalent to ZT8 in vivo, while expression remained comparatively low at other times including CT20. This suggests that the molecular clock tunes cardiomyocyte responsiveness to hypoxic stress in a circadian fashion, modulating protective gene programs like Areg expression.

Mechanistic investigations employing siRNA-mediated knockdown identified both BMAL1 and HIF2A as indispensable for hypoxia-triggered AREG induction, whereas silencing of closely related factors such as CLOCK or HIF1A failed to affect expression levels. These results elucidate a highly specific transcriptional regulatory axis, highlighting BMAL1–HIF2A as the critical heterodimeric complex governing this circadian response.

Extending these observations to genetically modified mice, myocardial IRI-induced Areg expression was significantly attenuated in cardiomyocytes deficient for either Bmal1 or Hif2a. This in vivo genetic evidence confirms the central role of the BMAL1–HIF2A pathway in orchestrating cardiomyocyte adaptive responses to ischemia-reperfusion injury on a time-of-day basis.

Biophysical analyses further elucidated the interaction dynamics within this transcriptional network. Surface plasmon resonance studies demonstrated direct binding of the BMAL1–HIF2A complex to the AREG promoter at conserved DNA motifs, including hypoxia response elements (HRE) and E-box sequences. Chromatin immunoprecipitation followed by quantitative PCR (ChIP-qPCR) validated the occupancy of these factors on the AREG promoter in both human embryonic kidney cells and cardiomyocytes, with significant circadian modulation observed.

Protein-protein interaction studies using co-immunoprecipitation confirmed the stable formation of the BMAL1–HIF2A heterodimer at specific circadian times in cardiomyocytes, correlating tightly with periods of high AREG expression. In luciferase reporter assays, the AREG promoter was potently activated by the BMAL1–HIF2A complex under hypoxic conditions, further underscoring the functional relevance of this heterodimeric interaction.

Collectively, these findings establish the BMAL1–HIF2A heterodimer as a master regulator of circadian-dependent gene expression programs in the ischemic heart, orchestrating protective mechanisms through rhythmic induction of factors like AREG. This work not only deepens our understanding of molecular cardiology but also points toward novel therapeutic avenues that leverage circadian biology to minimize myocardial injury.

The implications of these discoveries are profound. Circadian modulation of myocardial injury suggests that timing of interventions such as reperfusion therapies or pharmacological treatments could be optimized according to the patient’s internal biological clock. Targeting the BMAL1–HIF2A axis may enable development of drugs that enhance cardioprotection specifically during vulnerable time windows, mitigating damage and improving outcomes.

Moreover, the study elegantly integrates hypoxic signaling with circadian transcriptional control, illuminating how stress responses are temporally gated by intrinsic cellular clocks. This intersection of oxygen-sensing pathways and molecular chronobiology catalyzes a paradigm shift in how cardiovascular diseases are conceptualized, highlighting the importance of chronotherapy in clinical practice.

Future research building on these insights may explore the broader landscape of circadian-regulated genes involved in cardiac repair and remodeling, uncovering comprehensive temporal maps of gene networks activated during ischemic episodes. Additionally, the potential interplay between BMAL1–HIF2A and other circadian regulators or hypoxia-inducible factors warrants detailed dissection.

This landmark investigation sets the stage for translational applications aiming to harness circadian biology for cardioprotection. Through meticulous experimental design combining animal models, cellular assays, molecular biology techniques, and biophysical analyses, the authors have provided a compelling narrative linking molecular clock components to temporal dynamics of myocardial injury. Their work exemplifies the power of integrative science in addressing complex physiological phenomena.

As the global burden of ischemic heart disease continues to rise, understanding the temporal dimension of cardiac injury and repair emerges as a critical research frontier. The BMAL1–HIF2A heterodimer stands at this frontier as a promising molecular target, heralding new possibilities for personalized medicine tailored to the rhythms of human biology.

Subject of Research: Circadian regulation of myocardial injury and gene expression via the BMAL1–HIF2A heterodimer.

Article Title: BMAL1–HIF2A heterodimer modulates circadian variations of myocardial injury.

Article References:
Ruan, W., Li, T., Bang, I.H. et al. BMAL1–HIF2A heterodimer modulates circadian variations of myocardial injury. Nature (2025). https://doi.org/10.1038/s41586-025-08898-z

Image Credits: AI Generated